.png&w=384&q=75)
Bempedoic Acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors.
The recommended dosage of Bempedoic Acid, in combination with maximally tolerated statin therapy, is 180 mg administered orally once daily. Bempedoic Acid can be taken with or without food. After initiation of Bempedoic Acid, analyze lipid levels within 8 to 12 weeks.
Bempedoic Acid has serious interactions with no other drugs. Bempedoic Acid has moderate interactions with the following drugs: pravastatin. simvastatin.
None
Common side effects of Bempedoic Acid include:
Discontinue Bempedoic Acid when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. No available data regarding use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Data are not available regarding drug presence in human or animal milk, effects on breastfed infants, or effects on milk production
There is no clinical experience
Store at (20ºC to 25ºC).